Draflazine (BioDeep_00000178547)

   

human metabolite blood metabolite


代谢物信息卡片


1-{[(4-amino-2,6-dichlorophenyl)carbamoyl]methyl}-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide

化学式: C30H33Cl2F2N5O2 (603.1979242)
中文名称: 曲氟嗪
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: C1CN(C(CN1CCCCC(C2=CC=C(C=C2)F)C3=CC=C(C=C3)F)C(=O)N)CC(=O)NC4=C(C=C(C=C4Cl)N)Cl
InChI: InChI=1S/C30H33Cl2F2N5O2/c31-25-15-23(35)16-26(32)29(25)37-28(40)18-39-14-13-38(17-27(39)30(36)41)12-2-1-3-24(19-4-8-21(33)9-5-19)20-6-10-22(34)11-7-20/h4-11,15-16,24,27H,1-3,12-14,17-18,35H2,(H2,36,41)(H,37,40)

描述信息

C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent
D006401 - Hematologic Agents > D010975 - Platelet Aggregation Inhibitors
D020011 - Protective Agents > D002316 - Cardiotonic Agents
D002317 - Cardiovascular Agents

同义名列表

3 个代谢物同义名

1-{[(4-amino-2,6-dichlorophenyl)carbamoyl]methyl}-4-[5,5-bis(4-fluorophenyl)pentyl]piperazine-2-carboxamide; 2-Aminocarbonyl-N-(4-amino-2,6-dichlorophenyl)-4-(5,5-bis(4-fluorophenyl)-pentyl)-1-piperazineacetamide; Draflazine



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Natalia Grañe-Boladeras, Declan Williams, Zlatina Tarmakova, Katarina Stevanovic, Linda A Villani, Pedram Mehrabi, K W Michael Siu, Marçal Pastor-Anglada, Imogen R Coe. Oligomerization of equilibrative nucleoside transporters: a novel regulatory and functional mechanism involving PKC and PP1. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2019 03; 33(3):3841-3850. doi: 10.1096/fj.201800440rr. [PMID: 30521377]
  • Sumeeta Warraich, Derek B J Bone, Diana Quinonez, Hisataka Ii, Doo-Sup Choi, David W Holdsworth, Maria Drangova, S Jeffrey Dixon, Cheryle A Séguin, James R Hammond. Loss of equilibrative nucleoside transporter 1 in mice leads to progressive ectopic mineralization of spinal tissues resembling diffuse idiopathic skeletal hyperostosis in humans. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2013 May; 28(5):1135-49. doi: 10.1002/jbmr.1826. [PMID: 23184610]
  • James R Hammond, Meaghan Stolk, Richard G E Archer, Kristy McConnell. Pharmacological analysis and molecular cloning of the canine equilibrative nucleoside transporter 1. European journal of pharmacology. 2004 Apr; 491(1):9-19. doi: 10.1016/j.ejphar.2004.03.026. [PMID: 15102528]
  • Tohru Noji, Ken-ichiro Nan-ya, Chikako Katagiri, Mirai Mizutani, Jun-ichi Sano, Satoshi Nishikawa, Akira Karasawa, Hideaki Kusaka. Adenosine uptake inhibition ameliorates cerulein-induced acute pancreatitis in mice. Pancreas. 2002 Nov; 25(4):387-92. doi: 10.1097/00006676-200211000-00011. [PMID: 12409834]
  • E Snoeck, P Jacqmin, A Van Peer, M Danhof. A combined specific target site binding and pharmacokinetic model to explore the non-linear disposition of draflazine. Journal of pharmacokinetics and biopharmaceutics. 1999 Jun; 27(3):257-81. doi: 10.1023/a:1020943029130. [PMID: 10728489]
  • A Deussen, M Stappert, S Schäfer, M Kelm. Quantification of extracellular and intracellular adenosine production: understanding the transmembranous concentration gradient. Circulation. 1999 Apr; 99(15):2041-7. doi: 10.1161/01.cir.99.15.2041. [PMID: 10209010]
  • E Snoeck, K Ver Donck, P Jacqmin, H Van Belle, A G Dupont, A Van Peer, M Danhof. Physiological red blood cell kinetic model to explain the apparent discrepancy between adenosine breakdown inhibition and nucleoside transporter occupancy of draflazine. The Journal of pharmacology and experimental therapeutics. 1998 Jul; 286(1):142-9. doi: NULL. [PMID: 9655853]
  • E Snoeck, V Piotrovskij, P Jacqmin, A Van Peer, M Danhof, K Ver Donck, R Woestenborghs, H Van Belle, L Van Bortel, R Van Gool, A G Dupont, J Heykants. Population analysis of the non linear red blood cell partitioning and the concentration-effect relationship of draflazine following various infusion rates. British journal of clinical pharmacology. 1997 Jun; 43(6):603-12. doi: 10.1046/j.1365-2125.1997.00593.x. [PMID: 9205820]
  • B J Martin, R D Lasley, R M Mentzer. Infarct size reduction with the nucleoside transport inhibitor R-75231 in swine. The American journal of physiology. 1997 Apr; 272(4 Pt 2):H1857-65. doi: 10.1152/ajpheart.1997.272.4.h1857. [PMID: 9139972]
  • S Todo, Y Zhu, S Zhang, M B Jin, N Ishizaki, H Tanaka, V Subbotin, T E Starzl. Attenuation of ischemic liver injury by augmentation of endogenous adenosine. Transplantation. 1997 Jan; 63(2):217-23. doi: 10.1097/00007890-199701270-00007. [PMID: 9020320]
  • E Snoeck, V Piotrovskij, P Jacqmin, R L Lins, A Van Peer, M Danhof, R Woestenborghs, R Van Gool, A G Dupont, J Heykants. Population analysis of the non-linear red blood cell partitioning of draflazine following various infusion durations. European journal of clinical pharmacology. 1997; 53(1):57-63. doi: 10.1007/s002280050337. [PMID: 9349931]
  • E Snoeck, P Jacqmin, A Van Peer, M Danhof, K Ver Donck, H Van Belle, R Woestenborghs, R Crabbé, R Van Gool, A Dupont, J Heykants. The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine. British journal of clinical pharmacology. 1996 Nov; 42(5):605-13. doi: 10.1111/j.1365-2125.1996.tb00116.x. [PMID: 8951192]
  • G A Rongen, P Smits, K Ver Donck, J J Willemsen, R A De Abreu, H Van Belle, T Thien. Hemodynamic and neurohumoral effects of various grades of selective adenosine transport inhibition in humans. Implications for its future role in cardioprotection. The Journal of clinical investigation. 1995 Feb; 95(2):658-68. doi: 10.1172/jci117711. [PMID: 7860749]
  • M H Booster, M Yin, J G Maessen, B M Stubenitsky, R M Wijnen, G Kootstra. Protection of canine renal grafts by renin-angiotensin inhibition through nucleoside transport blockade. Transplant international : official journal of the European Society for Organ Transplantation. 1995; 8(3):207-13. doi: 10.1007/bf00336539. [PMID: 7626181]
  • H Van Belle, W Verheyen, K Ver Donck, P A Janssen, J I Robertson. Prevention of catecholamine-induced cardiac damage and death with a nucleoside transport inhibitor. Journal of cardiovascular pharmacology. 1992 Aug; 20(2):173-8. doi: 10.1097/00005344-199208000-00001. [PMID: 1381007]